Anders Johansson1, Kåre Buhlin2, Timo Sorsa2,3, Pirkko J Pussinen3. 1. Department of Odontology, Molecular Periodontology Research, Umeå University, Umeå, Sweden. 2. Department of Dental Medicine, Division of Periodontology, Karolinska Institute, Huddinge, Sweden. 3. Department of Oral and Maxillofacial Diseases, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Abstract
BACKGROUND: Leukotoxin (Ltx) expressed by Aggregatibacter actinomycetemcomitans is a powerful exotoxin, which can cause imbalance in host response. Immunoreactivity to Ltx is a marker for presence of leukotoxic A. actinomycetemcomitans, a presence that may modify the disease pattern of colonized individuals. The aim of the present study is to examine presence of systemic immunoreactivity to A. actionmycetemcomitans Ltx with respect to clinical and inflammatory findings in individuals with or without periodontitis (N = 88). METHODS: Periodontal status was examined in patients with severe periodontitis (n = 49) and healthy controls (n = 39), and patients received periodontal treatment. Systemic biomarkers associated with inflammation and infections as well as clinical parameters were analyzed at baseline and 3 and 6 months after treatment. RESULTS: Presence of immunoreactivity against Ltx was associated with impaired remission of disease after periodontal treatment. This immunoreactivity was also significantly associated with increased systemic levels of A. actinomycetemcomitans-specific immunoglobulins and increasing age. CONCLUSION: Presence and levels of systemic immunoreactivity against A. actinomycetemcomitans Ltx are associated with decreased remission after otherwise successful periodontal treatment.
BACKGROUND: Leukotoxin (Ltx) expressed by Aggregatibacter actinomycetemcomitans is a powerful exotoxin, which can cause imbalance in host response. Immunoreactivity to Ltx is a marker for presence of leukotoxic A. actinomycetemcomitans, a presence that may modify the disease pattern of colonized individuals. The aim of the present study is to examine presence of systemic immunoreactivity to A. actionmycetemcomitans Ltx with respect to clinical and inflammatory findings in individuals with or without periodontitis (N = 88). METHODS: Periodontal status was examined in patients with severe periodontitis (n = 49) and healthy controls (n = 39), and patients received periodontal treatment. Systemic biomarkers associated with inflammation and infections as well as clinical parameters were analyzed at baseline and 3 and 6 months after treatment. RESULTS: Presence of immunoreactivity against Ltx was associated with impaired remission of disease after periodontal treatment. This immunoreactivity was also significantly associated with increased systemic levels of A. actinomycetemcomitans-specific immunoglobulins and increasing age. CONCLUSION: Presence and levels of systemic immunoreactivity against A. actinomycetemcomitans Ltx are associated with decreased remission after otherwise successful periodontal treatment.
Entities:
Keywords:
Allergy and immunology; infection control; periodontitis
Authors: Eduardo Gomez-Bañuelos; Linda Johansson; Maximilian F Konig; Anders Lundquist; Merlin Paz; Kåre Buhlin; Anders Johansson; Solbritt Rantapää-Dahlqvist; Felipe Andrade Journal: J Clin Med Date: 2020-06-18 Impact factor: 4.241
Authors: Georgios N Belibasakis; Terhi Maula; Kai Bao; Mark Lindholm; Nagihan Bostanci; Jan Oscarsson; Riikka Ihalin; Anders Johansson Journal: Pathogens Date: 2019-11-06